SCHEDULE 13G/A: BlackRock Amends Stake in Travere Therapeutics, Disclosing 7.5% Passive Ownership

BlackRock, Inc. has filed an Amendment No. 11 to its Schedule 13G, reporting a 7.5% beneficial ownership stake in Travere Therapeutics, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 11 to its Schedule 13G regarding its beneficial ownership in Travere Therapeutics, Inc.
• As of March 31, 2025, BlackRock, Inc. beneficially owns 6,689,435 shares of Travere Therapeutics, Inc. Common Stock.
• This represents 7.5% of the total outstanding common shares of Travere Therapeutics, Inc.
• BlackRock holds sole voting power over 6,535,319 shares and sole dispositive power over 6,689,435 shares.
• The filing confirms that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• No single person's interest within BlackRock's holdings is more than five percent of the total outstanding common shares of Travere Therapeutics, Inc.
• BlackRock, Inc. also updated its Power of Attorney, effective January 21, 2025, revoking a previous one dated April 30, 2023, and authorizing specific individuals to execute SEC filings.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing indicating a significant, passive institutional investment. It is neutral in tone but the presence of a major investor like BlackRock can be seen as a positive signal of confidence in the company.

Positives

• BlackRock's continued significant stake (7.5%) indicates a long-term, passive investment interest in Travere Therapeutics, Inc.
• The filing confirms the investment is for ordinary course of business, not for control, which can signal stability for the issuer.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Travere Therapeutics, Inc.'s future performance or BlackRock's future investment intentions beyond the passive nature of the holding.

Management Comments

• The filing includes a certification by BlackRock, Inc. that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of Travere Therapeutics, Inc.

Industry Context

This filing is a routine disclosure by a major institutional investor, BlackRock, Inc., regarding its passive stake in a biotechnology company, Travere Therapeutics, Inc. Such filings are common and reflect portfolio adjustments by large asset managers rather than specific industry trends, though a significant stake by a firm like BlackRock can signal confidence in the sector or the specific company's long-term prospects.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory disclosure of beneficial ownership. It does not contain performance metrics or operational results that would allow for a direct comparison to industry standards or specific comparable companies/projects.
• The 7.5% stake is a significant institutional holding, typical for large asset managers like BlackRock in their diversified portfolios.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of BlackRock's 7.5% passive stake provides transparency regarding a significant institutional investor's position, which can be viewed positively as a vote of confidence in Travere Therapeutics, Inc.

Key Dates

Keywords

BlackRock, Travere Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, TRTX